Privo Technologies

Executive Summary

Privo Technologies is a privately held nanotechnology company headquartered in Cambridge, Massachusetts, focused on developing innovative therapeutics to eliminate cancers and prevent recurrence. Founded in 2019, the company has advanced its lead candidate to Phase 3 clinical trials, targeting improved and more accessible treatment options for diverse patient populations globally. Privo's platform leverages nanotechnology to enhance drug delivery, potentially improving efficacy and reducing side effects compared to conventional therapies. While the company has not yet disclosed its total funding or valuation, its progression to Phase 3 suggests significant clinical and operational milestones achieved. The company's commitment to addressing cancer recurrence and broadening treatment access positions it as a promising player in the oncology nanomedicine space. However, as a private entity, detailed financial and pipeline information remains limited, and final regulatory approval is still pending.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Trial Interim Data Readout60% success
• Q2 2026FDA End-of-Phase 2 Meeting and Phase 3 Trial Initiation75% success
• TBDStrategic Partnership or Licensing Deal50% success